CD8A and prostate carcinoma: Recently, a study reported no significant difference between TMB status and overall survival in some cancer types [14], and although the number of cases is not that large, even in prostate cancer, CD8-positive T cells do not correlate with the neoantigen load, and the objective response rate in TMB-high tumors was lower than that in TMB-low tumors.